Hana Pharm Co., Ltd. (293480.KS)
KRW 10850.0
(-0.73%)
KRW 10850.0
(-0.73%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 25.1 Billion KRW | 16.5% |
| 2022 | 21.55 Billion KRW | 418.12% |
| 2021 | 4.15 Billion KRW | 125.92% |
| 2020 | -16.04 Billion KRW | -68.39% |
| 2019 | -9.52 Billion KRW | 22.77% |
| 2018 | -12.33 Billion KRW | -176.62% |
| 2017 | 16.1 Billion KRW | -45.49% |
| 2016 | 29.54 Billion KRW | -14.55% |
| 2015 | 34.57 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 31.38 Billion KRW | 104.03% |
| 2024 Q1 | 15.38 Billion KRW | -38.75% |
| 2023 Q2 | 28.41 Billion KRW | 21.87% |
| 2023 Q1 | 23.31 Billion KRW | 8.19% |
| 2023 FY | 25.1 Billion KRW | 16.5% |
| 2023 Q4 | 25.1 Billion KRW | -12.56% |
| 2023 Q3 | 28.71 Billion KRW | 1.05% |
| 2022 Q1 | 30.56 Billion KRW | 634.85% |
| 2022 FY | 21.55 Billion KRW | 418.12% |
| 2022 Q4 | 21.55 Billion KRW | -36.92% |
| 2022 Q3 | 34.16 Billion KRW | 21.78% |
| 2022 Q2 | 28.05 Billion KRW | -8.21% |
| 2021 Q3 | -1.45 Billion KRW | 82.31% |
| 2021 Q4 | 4.15 Billion KRW | 385.01% |
| 2021 FY | 4.15 Billion KRW | 125.92% |
| 2021 Q1 | -15.86 Billion KRW | 1.17% |
| 2021 Q2 | -8.24 Billion KRW | 47.99% |
| 2020 Q3 | -9.07 Billion KRW | -27.4% |
| 2020 Q4 | -16.04 Billion KRW | -76.91% |
| 2020 FY | -16.04 Billion KRW | -68.39% |
| 2020 Q1 | -5.8 Billion KRW | 39.08% |
| 2020 Q2 | -7.12 Billion KRW | -22.64% |
| 2019 Q4 | -9.52 Billion KRW | -173.37% |
| 2019 FY | -9.52 Billion KRW | 22.77% |
| 2019 Q3 | 12.98 Billion KRW | 8.34% |
| 2019 Q1 | -15.36 Billion KRW | -24.5% |
| 2019 Q2 | 11.98 Billion KRW | 178.03% |
| 2018 FY | -12.33 Billion KRW | -176.62% |
| 2018 Q3 | 9.5 Billion KRW | -48.55% |
| 2018 Q4 | -12.33 Billion KRW | -229.79% |
| 2018 Q2 | 18.47 Billion KRW | 0.0% |
| 2017 FY | 16.1 Billion KRW | -45.49% |
| 2016 FY | 29.54 Billion KRW | -14.55% |
| 2015 FY | 34.57 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -185.25% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 95.611% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 91.923% |
| HANDOK Inc. | 283.45 Billion KRW | 91.142% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -25.091% |
| Yuhan Corporation | -69.18 Billion KRW | 136.291% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 87.054% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 781.217% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 95.152% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 177.419% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 66.821% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 31.84% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 69.573% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -185.25% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 115.708% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 87.505% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 85.312% |
| JW Holdings Corporation | 480.68 Billion KRW | 94.777% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 84.744% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -21263.133% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 83.735% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -967.843% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -9.16% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 85.65% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 51.691% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -185.25% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 84.138% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 92.99% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 83.735% |
| Yuhan Corporation | -69.18 Billion KRW | 136.291% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 81.537% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 57.924% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 94.149% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 83.735% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 78.399% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -52.866% |
| CKD Bio Corp. | 143.29 Billion KRW | 82.478% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 78.367% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 204.35% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 156.128% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -967.843% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 94.062% |
| Boryung Corporation | 187.72 Billion KRW | 86.625% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 134.95% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 66.821% |
| JW Lifescience Corporation | 26.09 Billion KRW | 3.765% |